验证法国 3 年预后评分在美国囊性纤维化人群中对死亡或肺移植的预测价值。
Validation of the French 3-year prognostic score for death or lung transplant in the United States cystic fibrosis population.
机构信息
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA.
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA.
出版信息
J Cyst Fibros. 2022 May;21(3):471-474. doi: 10.1016/j.jcf.2021.08.008. Epub 2021 Aug 28.
In 2017, Nkam et al. published a prognostic score to predict death or lung transplant within 3 years among adult cystic fibrosis (CF) patients. Their model was developed using French CF registry data and was subsequently validated in the Canadian CF registry. We evaluated this prognostic score using data from adult patients with CF in the United States (US) CF Foundation Patient registry, combined with lung transplant records from the United Network for Organ Sharing (UNOS) Registry (2013 to 2016) (n=11,542). We found that the prognostic score had a very good discriminative index predicting death or lung transplant in the US CF population (AUC 0.88, 95% CI 0.88-0.89) with an odds ratio (OR) of 2.83 (95% CI 2.69 - 2.97) for each unit increase in the score. However, it did not provide significant additional utility over an FEV ≤30% of predicted as a predictor of death or lung transplant.
2017 年，Nkam 等人发表了一项预后评分，用于预测成年囊性纤维化 (CF) 患者在 3 年内死亡或肺移植的风险。该模型基于法国 CF 登记数据开发，并随后在加拿大 CF 登记处得到验证。我们使用来自美国 CF 基金会患者登记处的成年 CF 患者数据，并结合来自器官共享联合网络 (UNOS) 登记处的肺移植记录（2013 年至 2016 年）（n=11542），对该预后评分进行了评估。我们发现，该预后评分在美国 CF 人群中具有很好的区分度，可以预测死亡或肺移植（AUC 0.88，95%CI 0.88-0.89），评分每增加一个单位，死亡或肺移植的风险比（OR）为 2.83（95%CI 2.69-2.97）。然而，与 FEV≤预测值的 30%相比，该评分作为死亡或肺移植的预测因子并未提供显著的额外效用。
Zotero 插件